Limiting activity at β1-subunit-containing GABAA receptor subtypes reduces ataxia

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 3, 2010, Pages 1040-1053

  Gee, Kelvin W ^a   Tran, Minhtam B ^a   Hogenkamp, Derk J ^a   Johnstone, Timothy B ^a   Bagnera, Rudy E ^a   Yoshimura, Ryan F ^a   Huang, Jin Cheng ^a   Belluzzi, James D ^a   Whittemore, Edward R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 128; 2 148; 2 247; 2 249; 2 261; 2 262; 2 301; 2 313; 2 314; 2 325; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; ALPRAZOLAM; BETA1 SUBUNIT CONTAINING GABA A RECEPTOR; BRETAZENIL; DIAZEPAM; ETOMIDATE; LORECLEZOLE; MEFENAMIC ACID; OCINAPLON; RECEPTOR SUBUNIT; TRACAZOLATE; UNCLASSIFIED DRUG; AMIDE; ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; BETA1 SUBUNIT, GABA A RECEPTOR; BETA1 SUBUNIT, GABA-A RECEPTOR; ISOPROTEIN;

ALLOSTERISM; ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; ATAXIA; BETA CHAIN; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENANTIOMER; EXPERIMENTAL MODEL; MALE; MOUSE; NEUROMODULATION; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; ROTAROD TEST; SEDATION; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; CHEMISTRY; DOSE RESPONSE; HUMAN; OOCYTE; PATCH CLAMP; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SPRAGUE DAWLEY RAT; STEREOISOMERISM; XENOPUS LAEVIS;

ALLOSTERIC REGULATION; AMIDES; ANIMALS; ANTI-ANXIETY AGENTS; ATAXIA; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA MODULATORS; HUMANS; MALE; MICE; OOCYTES; PATCH-CLAMP TECHNIQUES; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS LAEVIS;

EID: 77249140146     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.161885     Document Type: Article

References (40)

1. Asanuma C (1994) GABAergic and pallidal terminals in the thalamic reticular nucleus of squirrel monkeys. Exp Brain Res 101:439-451.
2. Astleford BA, Goe GL, Keay JG, and Scriven EFV (1989) Synthesis of 1-alkyl-1,2,4-triazoles: a new one-pot regiospecific procedure. J Org Chem 54:731-732.
3. Bare TM, McLaren CD, Campbell JB, Firor JW, Resch JF, Walters CP, Salama AI, Meiners BA, and Patel JB (1989) Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents. J Med Chem 32:2561-2573.
4. Basile AS, Lippa AS, and Skolnick P (2004) Anxioselective anxiolytics: can less be more? Eur J Pharmacol 500:441-451.
5. Bourin M, Hascoet M, Mansouri B, Colombel MC, and Bradwejn J (1992) Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models. J Psychiatry Neurosci 17:72-77.
6. Crabbe JC, Gallaher EJ, Cross SJ, and Belknap JK (1998) Genetic determinants of sensitivity to diazepam in inbred mice. Behav Neurosci 112:668-677.
7. Cryer B and Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104:413-421.
8. 2-adenosine receptors. Biochem Pharmacol 37:655-664.
9. de Haas SL, Franson KL, Schmitt JA, Cohen AF, Fau JB, Dubruc C, and van Gerven JM (2009) The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol 23:625-632.
10. de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, de Smet M, Vessey LK, Ramakrishnan R, Xue L, et al. (2008) Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol 22:24-32.
11. Fisher R and Blum D (1995) Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Epilepsia 36:S105-S114.
12. Groves JO, Guscott MR, Hallett DJ, Rosahl TW, Pike A, Davies A, Wafford KA, and Reynolds DS (2006) The role of GABAbeta2 subunit-containing receptors in mediating the anticonvulsant and sedative effects of loreclezole. Eur J Neurosci 24:167-174.
13. Halliwell RF, Thomas P, Patten D, James CH, Martinez-Torres A, Miledi R, and Smart TG (1999) Subunit-selective modulation of GABAA receptors by the non-steroidal anti-inflammatory agent, mefenamic acid. Eur J Neurosci 11: 2897-2905.
14. Hamon A, Morel A, Hue B, Verleye M, and Gillardin JM (2003) The modulatory effects of the anxiolytic etifoxine on GABA(A) receptors are mediated by the beta subunit. Neuropharmacology 45:293-303.
15. Harrison NL (2007) Mechanisms of sleep induction by GABA(A) receptor agonists. J Clin Psychiatry 68 (Suppl 5):6-12.
16. Hartings JA, Temereanca S, and Simons DJ (2000) High responsiveness and direction sensitivity of neurons in the rat thalamic reticular nucleus to vibrissa deflections. J Neurophysiol 83:2791-2801.
17. Hazrati LN and Parent A (1991) Projection from the external pallidum to the reticular thalamic nucleus in the squirrel monkey. Brain Res 550:142-146.
18. Heeres J (1985) inventor; Janssen Pharmaceutica N.V., assignee. 1-(2-Aryl-2-halo-1-ethenyl)-1H-azoles, and anticonvulsant use thereof. U.S. patent 4,539,325. 1985 Sept 3.
19. Hill-Venning C, Belelli D, Peters JA, and Lambert JJ (1997) Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor. Br J Pharmacol 120:749-756.
20. A receptor modulators. J Med Chem 50:3369-3379.
21. A receptor beta1 subunit. J Physiol 572: 459-475.
22. Litchfield JT Jr and Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-113.
23. Lippa A, Czobor P, Stark J, Beer B, Kostakis E, Gravielle M, Bandyopadhyay S, Russek SJ, Gibbs TT, Farb DH, et al. (2005) Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. Proc Natl Acad Sci U S A 102:7380-7385.
24. McCormick DA and Bal T (1997) Sleep and arousal: thalamocortical mechanisms. Annu Rev Neurosci 20:185-215.
25. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 3:587-592.
26. Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB, Zheng L, Stevens KE, and Gee KW (2007) Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci U S A 104:8059-8064.
27. Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, and Blin O (2006) Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 21:139-149.
28. Paré D, Hazrati LN, Parent A, and Steriade M (1990) Substantia nigra pars reticulata projects to the reticular thalamic nucleus of the cat: a morphological and electrophysiological study. Brain Res 535:139-146.
29. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, and Sperk G (2000) GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 101:815-850.
30. A receptors. J Pharmacol Exp Ther 319:1244-1252.
31. Putman DG, Hogenkamp DJ, Dasse OA, Whittemore ER, and Jensen MS (2007) inventors; Xytis Inc., assignee. Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use. World patent, WO109288. 2007 Sept 27.
32. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, and Möhler H (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 401:796-800.
33. Skolnick P and Epstein JW (2005) inventors. 2-Pyridinyl[7-(substituted- pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones. U.S. patent application 20050245517. 2005 Nov 3.
34. Smith AJ, Oxley B, Malpas S, Pillai GV, and Simpson PB (2004) Compounds exhibiting selective efficacy for different beta subunits of human recombinant gamma-aminobutyric acid A receptors. J Pharmacol Exp Ther 311:601-609.
35. A receptor partial allosteric activator, NG2-73: translational validity of pharmacokinetic/ pharmacodynamic (PK/PD) relationships derived from preclinical studies, in Proceedings of the Society for Neuroscience, 2007 Oct-Nov 7; San Diego, CA. Program no. 632.2/AAA17. Society for Neuroscience, Washington, DC.
36. A receptors in hippocampal granule cells. Brain Res 1029: 207-216.
37. Thompson SA, Wingrove PB, Connelly L, Whiting PJ, and Wafford KA (2002) Tracazolate reveals a novel type of allosteric interaction with recombinant gammaaminobutyric acid(A) receptors. Mol Pharmacol 61:861-869.
38. Van der Werf YD, Witter MP, and Groenewegen HJ (2002) The intralaminar and midline nuclei of the thalamus. Anatomical and functional evidence for participation in processes of arousal and awareness. Brain Res Brain Res Rev 39:107-140.
39. Van Dort CJ, Baghdoyan HA, and Lydic R (2009) Adenosine A(1) and A(2A) receptors in mouse prefrontal cortex modulate acetylcholine release and behavioral arousal. J Neurosci 29:871-881.
40. Whiting PJ (2006) GABA-A receptors: a viable target for novel anxiolytics? Curr Opin Pharmacol 6:24-29.